Quantcast
Last updated on April 17, 2014 at 15:21 EDT

Latest Metformin Stories

2013-07-03 12:24:23

NEWARK, Calif., July 3, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the JMP Securities Healthcare Conference at the St. Regis Hotel in New York City. The presentation at the JMP conference is scheduled for 11:30 am EDT (8:30 am PDT) on Tuesday, July 9, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be...

2013-06-23 20:20:04

Phase 3 Results for INVOKANA(TM) Demonstrate Novel Type 2 Diabetes Medicine Also Provided Greater Secondary Endpoint Reductions in Weight and Systolic Blood Pressure CHICAGO, June 23, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced results from a new 52-week Phase 3 clinical study, showing 300 milligrams (mg) of INVOKANA(TM) (canagliflozin) provided greater improvements in blood glucose control compared to a commonly prescribed therapy,...

2013-06-22 12:20:56

Studies assessing linagliptin alone and in combination with metformin in people with type 2 diabetes from China, Malaysia and the Philippines presented at the American Diabetes Association 73rd Scientific Sessions® RIDGEFIELD, Conn. and INDIANAPOLIS, June 22, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from two phase III clinical studies that showed linagliptin in Asian adults, as monotherapy and in...

2013-06-22 12:20:35

Data presented at the American Diabetes Association 73rd Scientific Sessions® also show statistically significant reductions in mean daily glucose and body weight in people with type 2 diabetes RIDGEFIELD, Conn. and INDIANAPOLIS, June 22, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results of two phase III 24-week clinical trials of the investigational agent empagliflozin(*) added to metformin with and without...

2013-06-20 12:31:04

RIDGEFIELD, Conn. and INDIANAPOLIS, June 20, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) announce the U.S. Food and Drug Administration (FDA) has approved updates to the full U.S. Prescribing Information (PI) for TRADJENTA(®) (linagliptin) tablets and JENTADUETO(®) (linagliptin and metformin hydrochloride) tablets. These updates are part of ongoing efforts to update product labels to ensure physicians, pharmacists and patients...

2013-06-17 23:14:23

To view the multimedia release and for additional information, please visit http://www.takedat2dtreatments.com. (PRWEB) June 17, 2013 Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that NESINA (alogliptin) and the fixed-dose combination therapies KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone) are now available by prescription in pharmacies in the United States (U.S.). These...

2013-06-17 12:28:22

DEERFIELD, Ill. and OSAKA, Japan, June 17, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that NESINA (alogliptin) and the fixed-dose combination therapies KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone) are now available by prescription in pharmacies in the United States (U.S.). These medications are approved by the U.S. Food and Drug Administration (FDA)...

2013-06-14 16:25:07

SAN DIEGO, June 14, 2013 /PRNewswire/ -- Elcelyx Therapeutics today announced that the company and principal investigator Ralph A. DeFronzo, M.D. will present posters related to NewMet(TM), a delayed-release formulation of generic metformin, at the 73(rd) Scientific Sessions of the American Diabetes Association in Chicago, IL. Dr. DeFronzo, Professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Science Center and the Audie L. Murphy Memorial Veterans...

2013-06-13 16:26:56

BOSTON, June 13, 2013 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced its support for the American Diabetes Association's (ADA) call for larger, longer-term, and more rigorous datasets and an independent review of pooled data on the safety of incretin-based diabetes medications, including GLP-1 analogs and DDP-4 inhibitors. The ADA made its announcement ahead of this week's NIDDK-NCI Workshop. Intarcia is currently conducting Phase 3 studies of its lead development candidate, ITCA...

2013-06-11 08:31:11

NEWARK, Calif., June 11, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Wells Fargo Securities 2013 Healthcare Conference at the Intercontinental Hotel in Boston, MA. The presentation at the Wells Fargo conference is scheduled for 11:15 am EDT (8:15 am PDT) on Wednesday, June 19, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of...